Marshall Wace
TCRT icon

Marshall Wace’s Alaunos Therapeutics TCRT Stock Holding History

Marshall Wace’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,011
Closed -$294K – 3093
2022
Q4 		$294K Sell
3,011
-10,063
-77% -$1.46M ﹤0.01% 2576
2022
Q3 		$3.37M Buy
13,074
+8,897
+213% +$2.58M 0.01% 1671
2022
Q2 		$777K Buy
+4,177
New +$399K ﹤0.01% 2585
2022
Q1 		– Sell
-871
Closed -$142K – 4005
2021
Q4 		$142K Sell
871
-2,588
-75% -$569K ﹤0.01% 3280
2021
Q3 		$944K Buy
+3,459
New +$1.06M ﹤0.01% 2056
2021
Q1 		– Sell
-325
Closed -$123K – 2846
2020
Q4 		$123K Sell
325
-28
-8% -$11.1K ﹤0.01% 1789
2020
Q3 		$133K Sell
353
-343
-49% -$152K ﹤0.01% 1503
2020
Q2 		$342K Buy
+696
New +$310K ﹤0.01% 1298
2019
Q2 		– Sell
-491
Closed -$283K – 1826
2019
Q1 		$283K Sell
491
-2,069
-81% -$865K ﹤0.01% 1272
2018
Q4 		$719K Buy
2,560
+2,321
+971% +$918K 0.01% 1004
2018
Q3 		$115K Buy
+239
New +$102K ﹤0.01% 1096

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Marshall Wace's TCRT Position: Q1 2023 in Review

Marshall Wace sold out of Alaunos Therapeutics (TCRT) in Q1 2023, closing a stake of 3,011 shares — an estimated $294K sold.

Marshall Wace first reported a position in TCRT in Q3 2018 and held it in 11 quarters. The position peaked at $3.37M in Q3 2022. 108 funds tracked by Wall St. Rank hold TCRT as of Q1 2023.

  • Marshall Wace reported no remaining Alaunos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Marshall Wace sold 3,011 Alaunos Therapeutics shares in Q1 2023, an estimated $294K.
  • Marshall Wace first reported a position in Alaunos Therapeutics in Q3 2018 and held it in 11 quarters.
  • Marshall Wace's Alaunos Therapeutics position peaked at $3.37M in Q3 2022.
  • 108 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.